This section will contain updates from the pain industry.

AAPM 2020 Resource Center Highlights

The AAPM 2020 Resource Center featured 65 companies presenting their products and services,160 scientific posters, and networking events – including popular Meet the Faculty sessions – held throughout the meeting. Learn ...
Continue reading
Topics:

FDA Approves Lundbeck’s Vyepti™ (eptinezumab-jjmr) – the First and Only Intravenous Preventive Treatment for Migraine

Read the full story .  
Topics:

FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis

​ Read the full story . 
Topics:

AAPM 2020 Ultrasound Preconference Course Supporters

On February 27, AAPM will feature the 2020 Advanced Ultrasound-Guided Pain Medicine Interventions preconference course. We would like to thank our Commercial Supporters for their dedication to pain medicine education by ...
Continue reading

More than 70 Industry Partners to Exhibit at AAPM 2020 Next Week

Preview a list of companies that will be exhibiting at the AAPM Annual Meeting February 27-March 1 in National Harbor. Learn about your therapeutic options for the treatment of acute and chronic pain. 

Continue reading
Topics:

BioElectronics Announces FDA Market Clearance for Over-The-Counter Treatment of Musculoskeletal Pain

BioElectronics Corporation is pleased to announce that it has obtained a new 510(k) clearance from the U.S. Food and Drug Administration (FDA). This new, over-the counter marketing clearance was granted for the drug...
Continue reading

Lilly's REYVOW™ (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute Treatment for Migraine (ditan), Now Available for Prescription

Eli Lilly and Company announced today that REYVOW™ (lasmiditan) C-V 50 mg and 100 mg tablets, an oral medication for the acute treatment of migraine with or without aura in adults, is now available for prescription and w...
Continue reading
Topics:

Novel Gene Therapies for Precision Pain Management Published by Pharmafile

 Article emphasizes the need of alternative approaches to manage pain and specifically focuses on the genetics of pain and gene therapy solutions. Full story.  
Topics:

Axsome Therapeutics Announces AXS-07 Achieves Co-Primary and Key Secondary Endpoints in MOMENTUM Phase 3 Migraine Trial in Patients with a History of Inadequate Response

Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that AXS-07, Axsome's novel, oral, multi-mech...
Continue reading
Topics:

Los Angeles Startup Uses AI to Reduce Unnecessary Spine Surgeries

A Los Angeles-based startup recently struck a licensing deal with the University of California- Los Angeles to create a tool that can analyze spine images to help decide whether patients should be a candidate for surgery.

Continue reading
Topics:

Want more pain resources? Check out our library of on-demand education, upcoming events, and more.

Learn More